Effectiveness and Tolerability of Mirabegron in Children with Overactive Bladder: A Retrospective Pilot Study
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Nov 2019 · 1 min read
In brief
In brief
This retrospective pilot study of 70 children with refractory overactive bladder found mirabegron improved symptoms in 70% of patients at 6 months, with 58% showing improvement in daytime incontinence and 60% in urinary frequency. Treatment was generally well-tolerated with normal cardiovascular monitoring, though 47% discontinued due to ineffectiveness or adverse effects including headaches and gastrointestinal symptoms.
Written by the GCMD Library team from the article.
Aims
Mirabegron has promising results for OAB symptoms in adults, although the potential for cardiovascular side effects has caused concern. Efficacy and tolerability in children have not been extensively studied. Effectiveness, tolerability, and side effects of Mirabegron are reported in children with refractory OAB.
Methods
A retrospective review of children receiving Mirabegron between February 2014 and November 2018 was completed. Frequency, urgency, nocturnal (NE), and daytime incontinence (DI) were analyzed at baseline and 6 months.
Results
70 children (50 females), median age 15 [range 8–16] years, commenced Mirabegron 25 mg (n = 29) or 50 mg (n = 41). 37 (53%) were still receiving treatment at 6 months: monotherapy n = 30, and combination therapy n = 7 (Solifenacin n = 4, Desmopressin n = 2, both n = 1). Where undertaken, blood pressure monitoring and ECGs were normal. For patients on monotherapy, 6 of 17 (35%) had improvement in NE, 11 of 19 (58%) in DI, 12 of 20 (60%) in frequency, and 8 of 21 (38%) in urgency symptoms. For patients receiving combination therapy, 2 of 6 (33%) had improvement in NE, 2 of 4 in DI (50%), 2 of 4 (50%) in frequency, and 4 of 6 (67%) had improvement in urgency. Reasons for treatment discontinuation (entire cohort) were: ineffectiveness (n = 28), worse symptoms (n = 4) and/or adverse reactions (n = 7), including dry mouth (n = 2), headaches (n = 4), dizziness (n = 1), nausea/vomiting (n = 3), increased seizures (n = 1), and rash (n = 1).
Conclusion
Mirabegron improved symptoms in 70% of patients with refractory OAB. A prospective RCT should be the next step to establish the role of Mirabegron for the treatment of OAB in children.
Level of evidence
Level II.